| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Mucosal Resection | 25 | 2024 | 113 | 10.140 |
Why?
|
| Colonoscopy | 12 | 2023 | 506 | 3.370 |
Why?
|
| Exocrine Pancreatic Insufficiency | 4 | 2024 | 34 | 2.860 |
Why?
|
| Colonic Polyps | 6 | 2023 | 212 | 2.730 |
Why?
|
| Pancreatitis, Chronic | 6 | 2024 | 127 | 2.320 |
Why?
|
| Adenoma | 6 | 2020 | 721 | 2.300 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 8 | 2024 | 172 | 2.240 |
Why?
|
| Stomach Neoplasms | 10 | 2023 | 2271 | 1.840 |
Why?
|
| Esophageal Neoplasms | 9 | 2024 | 3203 | 1.610 |
Why?
|
| Pancreatic Cyst | 4 | 2021 | 110 | 1.520 |
Why?
|
| Pancreatitis | 5 | 2021 | 282 | 1.480 |
Why?
|
| Barrett Esophagus | 4 | 2022 | 531 | 1.360 |
Why?
|
| Gastrectomy | 5 | 2020 | 473 | 1.330 |
Why?
|
| Endoscopy, Gastrointestinal | 7 | 2023 | 358 | 1.320 |
Why?
|
| Gastrointestinal Neoplasms | 6 | 2024 | 612 | 1.300 |
Why?
|
| Colorectal Neoplasms | 9 | 2023 | 3570 | 1.280 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 1396 | 1.230 |
Why?
|
| Gastric Mucosa | 4 | 2020 | 588 | 1.220 |
Why?
|
| Adenocarcinoma | 10 | 2024 | 7758 | 1.160 |
Why?
|
| Pancreatic Neoplasms | 10 | 2024 | 5168 | 1.010 |
Why?
|
| Endoscopy, Digestive System | 4 | 2021 | 197 | 1.010 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2019 | 165 | 1.010 |
Why?
|
| Early Detection of Cancer | 6 | 2020 | 1306 | 0.940 |
Why?
|
| Myotomy | 5 | 2024 | 17 | 0.940 |
Why?
|
| Esophagoscopy | 5 | 2024 | 295 | 0.930 |
Why?
|
| Fundoplication | 1 | 2024 | 67 | 0.900 |
Why?
|
| Colonic Diseases | 1 | 2023 | 73 | 0.860 |
Why?
|
| Sutures | 2 | 2022 | 90 | 0.810 |
Why?
|
| Humans | 91 | 2024 | 262697 | 0.770 |
Why?
|
| Colon | 2 | 2022 | 661 | 0.770 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 214 | 0.750 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 330 | 0.750 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 984 | 0.710 |
Why?
|
| Crohn Disease | 1 | 2023 | 317 | 0.700 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 223 | 0.700 |
Why?
|
| Suture Techniques | 1 | 2021 | 275 | 0.690 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 109 | 0.690 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2021 | 43 | 0.680 |
Why?
|
| Gastric Stump | 1 | 2019 | 3 | 0.670 |
Why?
|
| Natural Orifice Endoscopic Surgery | 4 | 2024 | 96 | 0.670 |
Why?
|
| Postoperative Complications | 7 | 2024 | 5446 | 0.670 |
Why?
|
| Intestinal Mucosa | 5 | 2023 | 1065 | 0.660 |
Why?
|
| Indomethacin | 1 | 2019 | 86 | 0.660 |
Why?
|
| Endosonography | 6 | 2022 | 541 | 0.660 |
Why?
|
| Stents | 4 | 2023 | 976 | 0.650 |
Why?
|
| Retrospective Studies | 27 | 2024 | 38842 | 0.640 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 1036 | 0.640 |
Why?
|
| Endoscopy | 3 | 2023 | 471 | 0.640 |
Why?
|
| Cholangitis | 2 | 2016 | 47 | 0.630 |
Why?
|
| Helicobacter pylori | 3 | 2023 | 1260 | 0.630 |
Why?
|
| Helicobacter Infections | 3 | 2023 | 1183 | 0.630 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 33 | 0.620 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 1719 | 0.610 |
Why?
|
| Malabsorption Syndromes | 1 | 2018 | 45 | 0.600 |
Why?
|
| Pancreatic Diseases | 3 | 2023 | 109 | 0.600 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2011 | 696 | 0.600 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 427 | 0.590 |
Why?
|
| Treatment Outcome | 23 | 2024 | 33142 | 0.590 |
Why?
|
| Catheter Ablation | 1 | 2022 | 553 | 0.590 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 361 | 0.580 |
Why?
|
| Biopsy, Needle | 1 | 2021 | 1377 | 0.560 |
Why?
|
| Esophagectomy | 1 | 2021 | 942 | 0.550 |
Why?
|
| Needles | 1 | 2017 | 102 | 0.550 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 166 | 0.550 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 4254 | 0.540 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 139 | 0.530 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 486 | 0.530 |
Why?
|
| Feces | 2 | 2018 | 799 | 0.530 |
Why?
|
| Dissection | 3 | 2021 | 133 | 0.520 |
Why?
|
| Pyloric Antrum | 1 | 2015 | 58 | 0.510 |
Why?
|
| Common Bile Duct | 1 | 2015 | 26 | 0.510 |
Why?
|
| Pancreas | 6 | 2023 | 717 | 0.490 |
Why?
|
| Male | 39 | 2024 | 124154 | 0.490 |
Why?
|
| Middle Aged | 30 | 2024 | 87462 | 0.490 |
Why?
|
| Intestinal Polyps | 1 | 2014 | 69 | 0.480 |
Why?
|
| Radiography, Abdominal | 1 | 2015 | 120 | 0.480 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 43 | 0.480 |
Why?
|
| Prospective Studies | 14 | 2024 | 12960 | 0.480 |
Why?
|
| Gastroparesis | 1 | 2015 | 81 | 0.470 |
Why?
|
| Female | 38 | 2024 | 143767 | 0.460 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 544 | 0.450 |
Why?
|
| Esophageal Achalasia | 2 | 2024 | 39 | 0.440 |
Why?
|
| Quality of Life | 4 | 2024 | 4623 | 0.440 |
Why?
|
| Sensitivity and Specificity | 6 | 2024 | 5009 | 0.430 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 402 | 0.420 |
Why?
|
| Cholagogues and Choleretics | 1 | 2012 | 36 | 0.420 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2012 | 52 | 0.420 |
Why?
|
| Esophageal Motility Disorders | 2 | 2024 | 14 | 0.420 |
Why?
|
| Colic | 1 | 2012 | 14 | 0.420 |
Why?
|
| Fluid Therapy | 2 | 2019 | 177 | 0.410 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2012 | 35 | 0.410 |
Why?
|
| Metaplasia | 3 | 2022 | 358 | 0.410 |
Why?
|
| Aged | 22 | 2024 | 71287 | 0.410 |
Why?
|
| Quality of Health Care | 1 | 2017 | 605 | 0.410 |
Why?
|
| Gallstones | 1 | 2012 | 62 | 0.410 |
Why?
|
| Biopsy | 2 | 2021 | 3399 | 0.410 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 227 | 0.400 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2012 | 77 | 0.400 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 438 | 0.390 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 576 | 0.390 |
Why?
|
| Financing, Government | 1 | 2011 | 38 | 0.380 |
Why?
|
| Margins of Excision | 2 | 2024 | 309 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 2620 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2390 | 0.370 |
Why?
|
| Birth Weight | 1 | 2012 | 342 | 0.360 |
Why?
|
| Research Support as Topic | 1 | 2011 | 117 | 0.360 |
Why?
|
| Bacteremia | 1 | 2015 | 688 | 0.330 |
Why?
|
| Mediastinum | 1 | 2011 | 274 | 0.330 |
Why?
|
| Pilot Projects | 4 | 2024 | 2795 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 10180 | 0.330 |
Why?
|
| Colonoscopes | 1 | 2009 | 22 | 0.330 |
Why?
|
| Adult | 16 | 2024 | 78789 | 0.310 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 409 | 0.310 |
Why?
|
| Lymphatic Metastasis | 4 | 2020 | 4902 | 0.300 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2018 | 85 | 0.290 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 519 | 0.290 |
Why?
|
| Microscopy, Confocal | 2 | 2019 | 656 | 0.280 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 30243 | 0.270 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2023 | 276 | 0.270 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 13777 | 0.260 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 1798 | 0.230 |
Why?
|
| Gels | 1 | 2024 | 106 | 0.230 |
Why?
|
| Risk Factors | 6 | 2024 | 17406 | 0.230 |
Why?
|
| Esophageal Stenosis | 1 | 2024 | 84 | 0.230 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 52 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2011 | 788 | 0.220 |
Why?
|
| Glycosides | 1 | 2023 | 20 | 0.220 |
Why?
|
| Case-Control Studies | 2 | 2024 | 5896 | 0.220 |
Why?
|
| Calculi | 1 | 2022 | 16 | 0.210 |
Why?
|
| Lithotripsy | 1 | 2022 | 23 | 0.210 |
Why?
|
| Pancreatic Ducts | 2 | 2022 | 126 | 0.210 |
Why?
|
| Risk Assessment | 4 | 2024 | 6763 | 0.210 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 161 | 0.210 |
Why?
|
| Cyst Fluid | 1 | 2021 | 22 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 4014 | 0.190 |
Why?
|
| Gastroscopy | 1 | 2022 | 139 | 0.190 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2021 | 8 | 0.190 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 336 | 0.190 |
Why?
|
| Tumor Burden | 2 | 2017 | 2004 | 0.190 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 251 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 4414 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 3057 | 0.190 |
Why?
|
| Rectum | 1 | 2023 | 469 | 0.180 |
Why?
|
| Japan | 2 | 2018 | 215 | 0.180 |
Why?
|
| Propensity Score | 1 | 2024 | 768 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 218 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2023 | 2879 | 0.170 |
Why?
|
| Endoscopes | 1 | 2019 | 38 | 0.160 |
Why?
|
| Bile Ducts | 1 | 2019 | 111 | 0.160 |
Why?
|
| Paclitaxel | 2 | 2024 | 2060 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2022 | 260 | 0.160 |
Why?
|
| Recurrence | 2 | 2021 | 4742 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 857 | 0.160 |
Why?
|
| Triglycerides | 1 | 2021 | 587 | 0.150 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2018 | 34 | 0.150 |
Why?
|
| Anemia | 1 | 2024 | 718 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 324 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 299 | 0.150 |
Why?
|
| Feasibility Studies | 3 | 2023 | 2319 | 0.150 |
Why?
|
| Proteome | 1 | 2021 | 567 | 0.150 |
Why?
|
| Cecum | 1 | 2017 | 38 | 0.150 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 90 | 0.150 |
Why?
|
| Ulcer | 1 | 2017 | 73 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 434 | 0.140 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 625 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2018 | 298 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 14834 | 0.130 |
Why?
|
| Time Factors | 3 | 2020 | 12669 | 0.130 |
Why?
|
| Jaundice | 1 | 2016 | 38 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 416 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 522 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2017 | 195 | 0.120 |
Why?
|
| Esophageal Sphincter, Lower | 2 | 2024 | 11 | 0.120 |
Why?
|
| Fatigue | 1 | 2020 | 1261 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 893 | 0.110 |
Why?
|
| Equipment Design | 1 | 2017 | 1171 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5440 | 0.110 |
Why?
|
| Adolescent | 5 | 2018 | 31577 | 0.110 |
Why?
|
| Abdominal Pain | 1 | 2016 | 368 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4860 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1790 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 908 | 0.100 |
Why?
|
| Cholecystectomy | 1 | 2012 | 112 | 0.100 |
Why?
|
| Texas | 3 | 2017 | 6275 | 0.100 |
Why?
|
| Research Design | 1 | 2018 | 1546 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2023 | 702 | 0.090 |
Why?
|
| Liver | 2 | 2022 | 2915 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1364 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6033 | 0.090 |
Why?
|
| United States | 5 | 2024 | 15693 | 0.090 |
Why?
|
| Enterotoxins | 1 | 1990 | 108 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 2236 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 2022 | 0.080 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2009 | 67 | 0.080 |
Why?
|
| Mercury Poisoning | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2012 | 366 | 0.080 |
Why?
|
| Young Adult | 3 | 2018 | 21749 | 0.080 |
Why?
|
| Retinitis Pigmentosa | 1 | 2009 | 83 | 0.080 |
Why?
|
| Inhalation Exposure | 1 | 2009 | 46 | 0.080 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 212 | 0.080 |
Why?
|
| Bacterial Toxins | 1 | 1990 | 220 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2014 | 1134 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4762 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 11573 | 0.080 |
Why?
|
| Music Therapy | 1 | 2008 | 17 | 0.080 |
Why?
|
| Eye Proteins | 1 | 2009 | 271 | 0.080 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2008 | 72 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 1053 | 0.080 |
Why?
|
| Bacteroides Infections | 1 | 2007 | 10 | 0.070 |
Why?
|
| Spondylitis | 1 | 2007 | 8 | 0.070 |
Why?
|
| Bacteroides fragilis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 434 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8884 | 0.070 |
Why?
|
| Escherichia coli Proteins | 1 | 1990 | 364 | 0.070 |
Why?
|
| Mass Screening | 1 | 2015 | 1519 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2024 | 100 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2008 | 154 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2008 | 147 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 205 | 0.070 |
Why?
|
| Warfarin | 1 | 2008 | 147 | 0.070 |
Why?
|
| Diarrhea | 1 | 1990 | 689 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 239 | 0.070 |
Why?
|
| Infant | 3 | 2018 | 13468 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 7581 | 0.070 |
Why?
|
| Colitis | 1 | 2009 | 336 | 0.060 |
Why?
|
| Survival Rate | 1 | 2019 | 12268 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2018 | 3008 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1991 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 16396 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 451 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8270 | 0.060 |
Why?
|
| Rats | 2 | 2023 | 6121 | 0.060 |
Why?
|
| Escherichia coli | 1 | 1990 | 1190 | 0.060 |
Why?
|
| Pancreatic Hormones | 1 | 2023 | 6 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2012 | 1272 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2023 | 135 | 0.050 |
Why?
|
| Inflammation | 2 | 2023 | 2479 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 90 | 0.050 |
Why?
|
| Hospitalization | 1 | 2012 | 2145 | 0.050 |
Why?
|
| Disaccharides | 1 | 2022 | 28 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2023 | 163 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 248 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2008 | 770 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 287 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 543 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 254 | 0.050 |
Why?
|
| Manometry | 1 | 2020 | 68 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2022 | 345 | 0.040 |
Why?
|
| Models, Animal | 1 | 2023 | 660 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 112 | 0.040 |
Why?
|
| Child | 3 | 2018 | 29575 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2022 | 530 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 426 | 0.040 |
Why?
|
| Fibrosis | 1 | 2023 | 739 | 0.040 |
Why?
|
| Bile | 1 | 2019 | 82 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7523 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2024 | 1019 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 75 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 408 | 0.040 |
Why?
|
| Optical Fibers | 1 | 2019 | 38 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2019 | 78 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 647 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 407 | 0.040 |
Why?
|
| Lasers | 1 | 2019 | 215 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 419 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 1451 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 91 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 146 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 174 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 261 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 693 | 0.040 |
Why?
|
| Resuscitation | 1 | 2019 | 241 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2020 | 551 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 834 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2024 | 1583 | 0.030 |
Why?
|
| Esophagus | 1 | 2019 | 542 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2022 | 9234 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1660 | 0.030 |
Why?
|
| Smoking | 1 | 2023 | 2388 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 1430 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 6746 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 963 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 2961 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2008 | 1507 | 0.030 |
Why?
|
| Malaysia | 1 | 1990 | 21 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1990 | 67 | 0.020 |
Why?
|
| Dark Adaptation | 1 | 2009 | 31 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 63 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 1055 | 0.020 |
Why?
|
| Electroretinography | 1 | 2009 | 120 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 5139 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 1990 | 116 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 7269 | 0.020 |
Why?
|
| Refractive Errors | 1 | 2009 | 72 | 0.020 |
Why?
|
| Visual Fields | 1 | 2009 | 142 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5705 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 59528 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 785 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2008 | 103 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5028 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 137 | 0.020 |
Why?
|
| Metronidazole | 1 | 2007 | 151 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 1088 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 5316 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 286 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 1295 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2009 | 804 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 11940 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 991 | 0.010 |
Why?
|
| Cross Infection | 1 | 2008 | 534 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 451 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 882 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 2538 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 16298 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1959 | 0.010 |
Why?
|